Why Guardant Health Stock Is Back on Investors’ Radar

Guardant Health (GH) moved into focus after several Q2 2026 developments, including FDA approval of an updated Guardant360 liquid biopsy test and new American Cancer Society support for its Shield colorectal cancer screening.

These clinical and guideline milestones arrived alongside stronger than expected Q1 results related to test volume and coverage trends. This provided investors with fresh information on how the company’s product portfolio is being used in practice.

Against this backdrop of clinical wins, Guardant Health’s stock has had a strong run, with a 90 day share price return of 64.65% and a 1 year total shareholder return of 171.85%, which points to building momentum rather than fading enthusiasm.

If Guardant Health’s recent move has you thinking about other healthcare data and diagnostics plays, it could be a good time to scan a wider field of 40 healthcare AI stocks.

After a 171.85% 1 year total return and a market value of about US$21.1b, Guardant Health now poses a tougher question for new investors: do the current figures still leave enough potential upside to justify the risk?

Most Popular Narrative: 6% Undervalued

The most followed narrative currently pegs Guardant Health’s fair value at about $171 per share, a little above the latest close of $161.67. That gap rests on a detailed set of growth and profitability assumptions that go well beyond the recent share price move.

Accelerating adoption of non-invasive blood-based cancer diagnostics is driving substantial growth across Guardant Health's key product lines (Guardant360 Liquid, Reveal, and Shield), expanding the company's total addressable market and supporting high double-digit revenue growth, with continued strong volume momentum and share gains documented for both new and established oncology applications.

Read the complete narrative. Read the complete narrative.

Want to see what is baked into that valuation gap for Guardant Health? The narrative leans heavily on compounded revenue growth, margin uplift, and a sharp swing toward profitability over the coming years.

Result: Fair Value of $171.08 (UNDERVALUED)

However, there are still execution risks around Shield payer adoption and Guardant Health’s ongoing cash burn that could challenge the upbeat valuation narrative.

Another View on Guardant Health’s Valuation

The popular narrative frames Guardant Health as modestly undervalued, yet the current P/S ratio of 18.3x is far higher than the US Healthcare industry average of 1.5x and the company’s own fair ratio estimate of 9.7x. That gap suggests meaningful valuation risk if sentiment cools. How comfortable are you with paying that kind of premium?

To see how the numbers line up against this richer pricing, including how revenue expectations and margins feed into that premium, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly mixed around Guardant Health, this is a moment to move quickly, review the full picture, and weigh the trade off between optimism and concern. To see the specific issues and bright spots that other investors are focused on, start with these 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond Guardant Health?

Do not stop your research with Guardant Health. The best opportunities often appear where others are not looking, so give yourself more options before making your next move.

• Target potential mispriced opportunities by reviewing a curated set of 53 high quality undervalued stocks that pair solid fundamentals with pricing that may not fully reflect their underlying business strength.
• Secure more dependable income streams by scanning 10 dividend fortresses that focus on companies offering higher yields with an eye on durability and consistency.
• Prioritise resilience by assessing 80 resilient stocks with low risk scores that emphasise stronger balance sheets and lower overall risk scores so surprises are less likely to catch you off guard.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.